Age-Related Macular Edema
Highlights from AAO 2024
In this episode of Meeting Mic, we bring you pearls and perspectives from the American Academy of Ophthalmology 2024 Meeting with a focus on AMD and retina.
Geographic Atrophy Secondary to Age-Related Macular Degeneration: Innovative Therapies for Sight Revival
This activity is supported by educational grants from Apellis Pharmaceuticals, Inc., and Topcon Healthcare, Inc.
Healio Minute Podcast, DME/Retina Edition: Top Headlines - Week of August 5, 2024
In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more.
Healio Minute Podcast, DME/Retina Edition: Top Headlines - Week of July 8, 2024
In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more.
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
Medical Crossfire<sup>®</sup>: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.
UBX1325 fails to meet noninferiority endpoint but performs better in longer-duration AMD
SEATTLE — In the phase 2 ENVISION trial, UBX1325 failed to meet the primary endpoint of noninferiority to aflibercept in wet age-related macular degeneration but showed comparable outcomes in a subgroup of advanced cases.